Insider buying last 90 days
No open-market insider purchases were filed for PRAX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PRAX insider filing, plotted on the chart in Gekko.Open PRAX in Gekko
NASDAQ: PRAX
Praxis Precision Medicines (PRAX) Stock Analysis & Forecast
Sep 28 close
$285.65+4.87 (+1.7%)
Gekko Brief
AI summaryThis week's coverage of Praxis Precision Medicines (PRAX) centers on institutional trading sentiment and analyst positioning. One piece describes weak near-term and mid-term sentiment alongside a strong long-term outlook, with strategies discussed for position trading and momentum breakout. Separately, brokerages covering the stock have given it an average recommendation of "Moderate Buy," with twenty ratings firms weighing in on the name.
PRAX closed at $285.65, up 1.7%, sitting between its 50-day average of $335.10 and 200-day average of $316.27. The stock has fallen 22.3% over one month and 18.5% over three months, though it remains up 480% over the past year. The GekkoIndex reads 74.5, placing PRAX in the Buying zone, down 1.1 over five sessions. Gekko Fair Value stands at $410.47, putting the current price 30.4% below that mark.
The next earnings report is scheduled for 9 November 2026, before the open, 41 days out and beyond a typical 20-trading-day holding window; the last report on 6 August showed an EPS of -2.87 against a -3.67 estimate, with a 13% reaction, and four beats across the last eight quarters. Congress recorded 2 buys and 0 sells over the past 90 days. Consensus among 15 firms shows 14 buy ratings and 1 hold, with a consensus target of $638.68. Seasonality over five years shows a 47% mean 20-day return from this point, with gains in 3 of those years.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Praxis Precision Medicines price vs fair value
Close $285.65200-day averageGekko Fair Value $410.47
Praxis Precision Medicines quick facts
- Market cap
- $7.96B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$12.96
- Revenue, TTM
- $7.46M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 2.78
- Volume
- 411,122 avg 409,510
- 1-year return
- +480.0%
- Typical daily move
- ±5.3%
- Typical 20-day move
- ±15.3%
- 50-day average
- $335.10
- 200-day average
- $316.27
- Next earnings
- Nov 9 before open
- Shares outstanding
- 27.92M
Praxis Precision Medicines swing-trade checklist
Praxis Precision Medicines scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $285.65 sits between the 50-day ($335.10) and 200-day ($316.27) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
74.5, Buying
Reading 74.5 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
30.4% below
Price is 30.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 2 buys / 0 sales.
See smart money - Earnings risksupportive
Reports in 41 days
Next report Nov 9, 2026, 41 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+47.0% on average
From this point in the calendar, the next 20 trading days averaged +47% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Praxis Precision Medicines stock chart and price history
Praxis Precision Medicines closed at $285.65 on Sep 28, 2026, +480.0% over the past year, inside a 52-week range of $48.64 to $392.70.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −22.3%
- 3 months
- −18.5%
- 6 months
- −1.5%
- 1 year
- +480.0%
The full PRAX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PRAX in Gekko
Follow Praxis Precision Medicines through every session
Put PRAX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PRAX in GekkoFree for 7 days. No credit card required.
About Praxis Precision Medicines
Praxis Precision Medicines works on drug candidates for disorders of the central nervous system linked to imbalances in neuronal signaling, and has not yet brought a product to market. Its furthest-along programs are PRAX-114, a compound acting on the GABAA receptor being tested in mid-stage trials for major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel inhibitor being studied for essential tremor. It is also testing PRAX-562 for pediatric epilepsy and adult headache conditions, and developing genetic-targeted therapies for SCN2A and KCNT1 forms of epilepsy.
Its pipeline is built in part through outside partnerships rather than solely in-house work. Praxis has a licensing and cooperation agreement with RogCon, a license with Purdue Neuroscience Company, a research and licensing collaboration with Ionis Pharmaceuticals, and a joint effort with The Florey Institute to develop additional antisense therapies.
The company was founded in 2015 and is headquartered in Boston, Massachusetts. Its shares are listed on the NASDAQ under the ticker PRAX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- praxismedicines.com
Praxis Precision Medicines GekkoIndex: the smart money zone
Praxis Precision Medicines’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 74.5, in the Buying zone, down 1.1 points over five sessions.
74.5Buying
Down 1.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 36 | Not available | |||
| Accumulation | 154 | Not available | |||
| Neutral | 430 | +3.5% | +14.7% | ||
| Distribution | 47 | +1.3% | −2.9% | ||
| Selling | 5 | Too few readings yet | |||
Average PRAX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the PRAX price, zone by zone.Track PRAX in Gekko
Is Praxis Precision Medicines stock overvalued? Gekko Fair Value
Praxis Precision Medicines trades 30.4% below Gekko Fair Value of $410.47, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Praxis Precision Medicines shares are worth, recalculated every trading day.
$410.47
Gekko Fair Value, Sep 26, 2026
30.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open PRAX in Gekko
Praxis Precision Medicines insider and Congress trading
No open-market insider purchases were filed for Praxis Precision Medicines, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Ray Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 7 traded Jul 30 |
| Gilbert Ray Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 7 traded Jul 29 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Praxis Precision Medicines has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2024
- $1K
- As a share of market cap
- 0.00%
From company filings.
Praxis Precision Medicines earnings: next date and track record
Praxis Precision Medicines reports on Nov 9, 2026, before the open (41 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 9, 2026
Expected before the open, 41 days away
- EPS estimate
- −$3.65
- Revenue estimate
- $131K
4 of 8reports beat the EPS estimate
±10.5%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Praxis has two NDAs under FDA review with approvals expected within six months: ulixacaltamide for essential tremor (PDUFA January 2027) and relutrigine for SCN2A/SCN8A developmental epileptic encephalopathy (PDUFA December 27, 2026). FDA mid-cycle communications confirmed no efficacy issues and no advisory committee meetings planned for either drug. Commercial infrastructure is fully built including field force, distribution networks, and patient support programs. EMERALD study enrolled ~200 patients across 50+ genetically defined epilepsies, targeting a supplemental NDA in 2027.
- Guidance
- Two product launches expected within six months pending FDA approval. Relutrigine approval would qualify for a pediatric review voucher. EMERALD data could support a supplemental NDA for broader DEE indications in 2027.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$2.87 est −$3.67 | — est $1.25M | +13.0% |
| May 7, 2026 | −$3.20 est −$3.68 | — est $100K | −2.4% |
| Feb 19, 2026 | −$3.50 est −$3.13 | — est $67K | +1.9% |
| Nov 5, 2025 | −$3.36 est −$3.45 | — est $256K | +0.3% |
| Aug 4, 2025 | −$3.31 est −$3.36 | — est $59K | −11.6% |
| May 2, 2025 | −$3.29 est −$3.21 | — est $199K | +2.4% |
| Feb 28, 2025 | −$2.94 est −$2.82 | $7.46M est $298K | −48.4% |
| Nov 6, 2024 | −$2.75 est −$1.95 | — | +3.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Praxis Precision Medicines stock forecast and analyst price targets
Analysts’ average 12-month price target for Praxis Precision Medicines is $638.68, +123.6% from the last close, from 15 firms rating the stock in the last 90 days.
$638.68consensus 12-month target, +123.6% from the last close
Now $285.65Avg $638.68
Low $362High $1,201
Each firm’s latest rating in the last 90 days: 15 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Needham | $582 | +103.7% |
| Sep 24 | H.C. Wainwright | $1,201 | +320.4% |
| Aug 21 | Goldman Sachs | $575 | +101.3% |
| Aug 17 | Oppenheimer | $650 | +127.6% |
| Aug 17 | Raymond James | $945 | +230.8% |
+47.0%average move over the next 20 trading days in the last 5 years
±5.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Praxis Precision Medicines seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Praxis Precision Medicines averaged +47.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | 0.0% | 2 of 5 |
| Next 10 trading days | −5.2% | 1 of 5 |
| Next 15 trading days | +42.3% | 3 of 5 |
| Next 20 trading days | +47.0% | 3 of 5 |
| Next 30 trading days | +42.6% | 3 of 5 |
For scale, PRAX’s typical 20-trading-day move in either direction is about 15.3%.
Praxis Precision Medicines market cap and key statistics
Praxis Precision Medicines’s market cap is $7.96B and revenue of $7.46M over the last twelve months.
Valuation
- Market cap
- $7.96B
- EPS, TTM
- −$12.96
- Gekko Fair Value
- $410.47
Trading
- Volume
- 411,122
- Avg volume, 20 days
- 409,510
- 52-week high
- $392.70
- 52-week low
- $48.64
- Shares outstanding
- 27.92M
Financials
- Revenue, TTM
- $7.46M
- Profit margin
- 0%
- Return on equity
- -38.9%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.78
- Typical daily move
- ±5.3%
- Typical 20-day move
- ±15.3%
Praxis Precision Medicines stock news this week
2 headlines about Praxis Precision Medicines from the past week, newest first, each linking to the publisher.
- (PRAX) as a Liquidity Pulse for Institutional TacticsStock Traders Daily, Sep 25
- Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of “Moderate Buy” by BrokeragesDefense World, Sep 21
Praxis Precision Medicines peers
Praxis Precision Medicines’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Praxis Precision Medicines stock FAQ
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $7.96B at the Sep 28, 2026 close of $285.65, with 27.92M shares outstanding.
What is the Praxis Precision Medicines stock forecast?
The consensus analyst 12-month price target for Praxis Precision Medicines is $638.68, +123.6% from the last close. Of the 15 firms that rated the stock in the last 90 days, 14 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Praxis Precision Medicines stock overvalued or undervalued?
On Gekko’s estimate Praxis Precision Medicines is undervalued: the Sep 28, 2026 close of $285.65 is 30.4% below Gekko Fair Value of $410.47. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Praxis Precision Medicines report earnings next?
Praxis Precision Medicines is expected to report on Nov 9, 2026, before the market opens (41 days away). Analysts expect earnings of −$3.65 per share on revenue of $131K. Praxis Precision Medicines beat the earnings estimate in 4 of its last 8 reports, moving 10.5% on average across the report.
What is Praxis Precision Medicines’s 52-week high and low?
Praxis Precision Medicines’s 52-week high is $392.70 and its 52-week low is $48.64; it closed at $285.65 on Sep 28, 2026, +480.0% over the past year.
Is Praxis Precision Medicines stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Praxis Precision Medicines the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.